← All trials
NCT05155579
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2022
- Primary completion
- Apr 30, 2024
- Completion date
- Aug 31, 2024
- First posted
- Dec 13, 2021
- Last posted
- Dec 13, 2021
- Enrollment
- 590
- Arms / groups
- 9 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OxfordLead sponsor
- University of OxfordOverall official - principal investigator
- Malaria Research and Training Center, Bamako, MaliCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.